<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00176878</url>
  </required_header>
  <id_info>
    <org_study_id>MT2000-18</org_study_id>
    <secondary_id>9504M09637</secondary_id>
    <nct_id>NCT00176878</nct_id>
    <nct_alias>NCT00005895</nct_alias>
  </id_info>
  <brief_title>Stem Cell Transplant for Bone Marrow Failure Syndromes</brief_title>
  <official_title>Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers hypothesize that it will be possible to perform unrelated bone marrow or cord
      blood transplants in a safer manner by using less intensive therapy yet still achieve an
      acceptable level of donor cell engraftment for non-malignant congenital bone marrow failure
      disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to transplantation, subjects will receive the drugs busulfan (orally or through the
      catheter), as well as fludarabine and anti-thymocyte globulin (ATG) via the catheter.
      Busulfan, fludarabine and ATG will be given with Total Lymphoid Irradiation (TLI) to help the
      new donor bone marrow take and grow after transplantation.

      Those patients receiving donor marrow will have the T cells (a type of white blood cell in
      the donor marrow) removed to lower the risk that the new marrow will react to their body, a
      condition called Graft-Versus-Host-Disease (GVHD). After bone marrow transplantation,
      subjects will receive drugs to help prevent GVHD, including cyclosporin and mycophenolate
      mofetil (MMF).

      Blood samples are taken at day 28, day 60, day 100, 1 year and as required by medical status
      yearly for five years after transplant to evaluate how well the new marrow is growing. A bone
      marrow biopsy is required at day 21, at day 100 and 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Alive (Survival) at 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>Calculated from day 1 of transplant to last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Alive at Three Years (Survival)</measure>
    <time_frame>3 years</time_frame>
    <description>Number of subjects who survived 3 years post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Succcessful Engraftment After Transplantation</measure>
    <time_frame>42 Days</time_frame>
    <description>Number of patients who received non-genotypic identical marrow or cord blood cells using a &quot;non-myeloablative&quot; preparative regimen and exhibited engraftment at Day 42.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Grade 2-4 Acute Graft Versus Host Disease</measure>
    <time_frame>100 Days</time_frame>
    <description>Number of patients with Grade 2, 3 and 4 Acute (normally observed within the first 100 days) Graft Versus Host Disease. Acute GVHD is staged as follows: overall grade (skin-liver-gut) with each organ staged individually from a low of 1 to a high of 4. Patients with grade IV GVHD usually have a poor prognosis. Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Chronic Graft Versus Host Disease</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients who exhibited chronic (normally occurs after 100 days) Graft Versus Host Disease at 2 years post transplant. Chronic graft-versus-host-disease, over its long-term course, can also cause damage to the connective tissue and exocrine glands.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Disease Recurrence</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients who exhibited disease recurrence at 2 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Diamond-Blackfan Anemia</condition>
  <condition>Kostmann's Neutropenia</condition>
  <condition>Shwachman-Diamond Syndrome</condition>
  <arm_group>
    <arm_group_label>Bone Marrow Failure Disorders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell transplant</intervention_name>
    <description>Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10^9/kg.</description>
    <arm_group_label>Bone Marrow Failure Disorders</arm_group_label>
    <other_name>BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine monophosphate</intervention_name>
    <description>fludarabine 175 mg/m^2 (total) on Days -6 through -3.</description>
    <arm_group_label>Bone Marrow Failure Disorders</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total lymphoid irradiation</intervention_name>
    <description>Dose 500 cGy radiation therapy to specific areas of the body</description>
    <arm_group_label>Bone Marrow Failure Disorders</arm_group_label>
    <other_name>TLI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),</description>
    <arm_group_label>Bone Marrow Failure Disorders</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter</description>
    <arm_group_label>Bone Marrow Failure Disorders</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients eligible for transplantation under this protocol will be &lt;35 years of age,
             and will be diagnosed with:

               -  a bone marrow failure syndrome unresponsive to available therapy, including but
                  not limited to Diamond-Blackfan anemia, Shwachman Diamond syndrome or Kostmann's
                  neutropenia but exclusive of aplastic anemia.

          -  Diamond Blackfan Anemia:

               -  Patients must show evidence of steroid resistance requiring equivalent of &gt;6
                  transfusions yearly despite steroid therapy.

               -  Evidence of developing aplasia or myelodysplasia will also be criteria for
                  transplantation.

          -  Kostmann's Neutropenia, Shwachman-Diamond syndrome:

               -  Patients must have been previously diagnosed as having a clinical picture
                  characteristic of Shwachman-Diamond syndrome (exocrine pancreatic insufficiency,
                  growth retardation, metaphyseal dysostosis, neutropenia), or must have a bone
                  marrow aspirate consistent with Kostmann's neutropenia, with no evidence of acute
                  leukemia.

               -  Patients must have failed therapy with granulocyte-colony stimulating factor
                  (G-CSF), as determined by an inability to maintain an absolute neutrophil count
                  (ANC) &gt;750 cells/ml(3), or manifesting recurrent infections despite G-CSF
                  administration resulting in life threatening infections or repeated
                  hospitalizations (&lt;4 /year).

        Exclusion Criteria:

          -  Patients &gt;35 years of age

          -  Karnofsky score &lt;70%

          -  Hepatic dysfunction as determined by bilirubin &gt;3.0, ALT &gt;150, or active hepatitis

          -  Pulmonary function tests with forced volume vital capacity (FVC) and forced expiratory
             volume (FEV) &lt;70%; O2 saturation &lt;94%

          -  Renal dysfunction with glomerular filtration rate (GFR) &lt;30% of predicted.

          -  Cardiac compromise, with left ejection fraction &lt;45%.

          -  Severe, stable neurologic impairment.

          -  Human immunodeficiency virus (HIV) positivity.

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Orchard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>June 18, 2009</results_first_submitted>
  <results_first_submitted_qc>June 18, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 6, 2009</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stem cell transplant</keyword>
  <keyword>T-cell depletion</keyword>
  <keyword>TLI</keyword>
  <keyword>bone marrow failure disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Anemia, Diamond-Blackfan</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Lipomatosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bone Marrow Failure Patients</title>
          <description>All patients with non-malignant, congenital bone marrow failure disorders and treated with stem cell transplant, chemotherapy (Busulfan, ATG, Fludarabine) and irradiation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bone Marrow Failure Patients</title>
          <description>All patients with non-malignant, congenital bone marrow failure disorders and treated with stem cell transplant, chemotherapy (Busulfan, ATG, Fludarabine) and irradiation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Alive (Survival) at 2 Years</title>
        <description>Calculated from day 1 of transplant to last contact.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow Failure Patients</title>
            <description>All patients with non-malignant, congenital bone marrow failure disorders and treated with stem cell transplant, chemotherapy (Busulfan, ATG, Fludarabine) and irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive (Survival) at 2 Years</title>
          <description>Calculated from day 1 of transplant to last contact.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Alive at Three Years (Survival)</title>
        <description>Number of subjects who survived 3 years post-transplant.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow Failure Patients</title>
            <description>All patients with non-malignant, congenital bone marrow failure disorders and treated with stem cell transplant, chemotherapy (Busulfan, ATG, Fludarabine) and irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Alive at Three Years (Survival)</title>
          <description>Number of subjects who survived 3 years post-transplant.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Succcessful Engraftment After Transplantation</title>
        <description>Number of patients who received non-genotypic identical marrow or cord blood cells using a &quot;non-myeloablative&quot; preparative regimen and exhibited engraftment at Day 42.</description>
        <time_frame>42 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow Failure Patients</title>
            <description>All patients with non-malignant, congenital bone marrow failure disorders and treated with stem cell transplant, chemotherapy (Busulfan, ATG, Fludarabine) and irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Succcessful Engraftment After Transplantation</title>
          <description>Number of patients who received non-genotypic identical marrow or cord blood cells using a &quot;non-myeloablative&quot; preparative regimen and exhibited engraftment at Day 42.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Grade 2-4 Acute Graft Versus Host Disease</title>
        <description>Number of patients with Grade 2, 3 and 4 Acute (normally observed within the first 100 days) Graft Versus Host Disease. Acute GVHD is staged as follows: overall grade (skin-liver-gut) with each organ staged individually from a low of 1 to a high of 4. Patients with grade IV GVHD usually have a poor prognosis. Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening.</description>
        <time_frame>100 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow Failure Patients</title>
            <description>All patients with non-malignant, congenital bone marrow failure disorders and treated with stem cell transplant, chemotherapy (Busulfan, ATG, Fludarabine) and irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Grade 2-4 Acute Graft Versus Host Disease</title>
          <description>Number of patients with Grade 2, 3 and 4 Acute (normally observed within the first 100 days) Graft Versus Host Disease. Acute GVHD is staged as follows: overall grade (skin-liver-gut) with each organ staged individually from a low of 1 to a high of 4. Patients with grade IV GVHD usually have a poor prognosis. Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Chronic Graft Versus Host Disease</title>
        <description>Number of patients who exhibited chronic (normally occurs after 100 days) Graft Versus Host Disease at 2 years post transplant. Chronic graft-versus-host-disease, over its long-term course, can also cause damage to the connective tissue and exocrine glands.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow Failure Patients</title>
            <description>All patients with non-malignant, congenital bone marrow failure disorders and treated with stem cell transplant, chemotherapy (Busulfan, ATG, Fludarabine) and irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Chronic Graft Versus Host Disease</title>
          <description>Number of patients who exhibited chronic (normally occurs after 100 days) Graft Versus Host Disease at 2 years post transplant. Chronic graft-versus-host-disease, over its long-term course, can also cause damage to the connective tissue and exocrine glands.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Disease Recurrence</title>
        <description>Number of patients who exhibited disease recurrence at 2 years.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bone Marrow Failure Patients</title>
            <description>All patients with non-malignant, congenital bone marrow failure disorders and treated with stem cell transplant, chemotherapy (Busulfan, ATG, Fludarabine) and irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Disease Recurrence</title>
          <description>Number of patients who exhibited disease recurrence at 2 years.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 of study up through 1 year</time_frame>
      <desc>Only serious adverse events are reported. Other adverse events were not collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bone Marrow Failure Patients</title>
          <description>All patients with non-malignant, congenital bone marrow failure disorders and treated with stem cell transplant, chemotherapy (Busulfan, ATG, Fludarabine) and irradiation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bone marrow graft failure</sub_title>
                <description>Autologous recovery, Chimerism (secondary)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Graft-versus-host disease (acute)</sub_title>
                <description>Grade III-IV</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pharmacokinetic parameters in patients receiving 2 mg/kg/dose of busulfan twice daily was not performed. No data is available.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul Orchard, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-626-2313</phone>
      <email>orcha001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

